Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Inv. presentation

Praxis Precision Medicines, Inc. (PRAX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
10/02/2023 8-K Quarterly results
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results On track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA",
"PLATFORM PRAX-090 PRAX-222 PRAX-080 PRAX-100"
07/03/2023 SC 13G/A Cormorant Global Healthcare Master Fund, LP reports a 7.4% stake in Praxis Precision Medicines, Inc.
06/30/2023 SC 13G ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 6.2% stake in Praxis Precision Medicines, Inc.
06/30/2023 SC 13G Venrock Healthcare Capital Partners III, L.P. reports a 9.1% stake in Praxis Precision Medicines, Inc.
06/28/2023 SC 13D/A Velan Capital Investment Management LP reports a 4% stake in Praxis Precision Medicines, Inc.
06/16/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
06/15/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
06/15/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/09/2023 8-K Other Events  Interactive Data
06/08/2023 SC 13G/A BlackRock Inc. reports a 4.7% stake in PRAXIS PRECISION MEDICINES, INC.
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023",
"PLATFORM PRAX-090 PRAX-222 PRAX-080 PRAX-100"
04/27/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/17/2023 8-K Quarterly results
03/21/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Praxis Precision Medicines, Inc. 99 High Street, 30 th Floor Boston, MA 02110"
03/20/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/10/2023 SC 13G Huang James reports a 5.1% stake in Praxis Precision Medicines, Inc.
03/03/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ESSENTIAL1 ESSENTIAL TREMOR TOPLINE RESULTS"
02/14/2023 SC 13G/A Point72 Asset Management, L.P. reports a 2.2% stake in Praxis Precision Medicines, Inc.
02/14/2023 SC 13G/A PFM Health Sciences, LP reports a 5.9% stake in Praxis Precision Medicines, Inc.
02/14/2023 SC 13G/A EVENTIDE ASSET MANAGEMENT, LLC reports a 7.5% stake in Praxis Precision Medicines, Inc.
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/07/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/07/2023 10-K Annual Report for the period ended December 31, 2022
02/07/2023 8-K Quarterly results
Docs: "Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results Ulixacaltamide Phase 2b Essential1study topline results for essential tremor expected in 1Q23&#59; Praxis to enter quiet period following market close on Thursday, February 9",
"PLATFORM PRAX-090 PRAX-222 PRAX-080 PRAX-020 PRAX-030 PRAX-050 PRAX-100"
02/07/2023 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
02/02/2023 SC 13G Avidity Partners Management LP reports a 8.7% stake in Praxis Precision Medicines, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy